Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Daily almonds may tame gut inflammation in metabolic syndrome

NCT ID NCT05790564

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether eating almonds every day for 12 weeks can improve gut health and lower inflammation in people with metabolic syndrome. About 80 adults aged 35-60 with conditions like high blood pressure, high blood sugar, or unhealthy cholesterol levels will participate. Researchers will measure changes in gut barrier function, inflammation markers, and heart health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2022

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 35-60 years * 3 or more of the following: hypertension (systolic BP 130-179 mmHg or diastolic BP 85-119 mmHg); hyperglycemia (fasting glucose 100-599 mg/dL); central obesity \[waist circumference greater than 40.1 inches (M) or 34.6 inches (F); hypertriglyceridemia (150-499 mg/dL); low HDL \[lower than 40 mg/dL (M) or 50 mg/dL (F)\] * Willing to restrict consumption of nuts other than study nuts for 1 week prior to and throughout the study (13 weeks) * Willing to stop probiotic supplements one week prior to and during the study (13 weeks) * Willing to stop multivitamins and supplements containing vitamin E, magnesium, calcium, iron, zinc and copper one week prior to and during the study (13 weeks) * Willing to complete intake diaries during the study * Willing to maintain current eating patterns (no significant diet change during study) Exclusion Criteria: * Weekly consumption of almonds, hazelnuts, peanuts and sunflower seeds combined greater than 2 servings (about 2 oz) in the past 3 months * Nut, wheat, or gluten allergy/intolerance * Regular use of vitamin E supplements * Consume more than 2 alcoholic drinks daily * Tobacco use, including e-cigarettes, or smoking of any substance (e.g. cannabis) in the past 3 months * Pregnancy, breastfeeding, or planning to become pregnant before completing the study * Vigorous exercise greater than 7 hours/week * History of cardiovascular disease, liver disease or cancer * Have had bariatric surgery (e.g. gastric bypass, gastric banding, sleeve gastrectomy, etc.), other gastrointestinal procedures (e.g. cholecystectomy), disorders (e.g. Crohn's disease, celiac disease, ulcerative colitis) or chronic diarrhea * Diagnosis of hemochromatosis * Chronic use (daily intake in past 30 days) of anti-inflammatory medication (steroid or NSAID) * Use of ezetimibe or orlistat * Use of oral antibiotic medication within the past month * Body Mass Index (BMI) \<25.0 or \>35.0 kg/m2 * Regular use of multivitamin supplements in the past 3 months * Physician prescribed use of probiotic, vitamin E, magnesium, calcium, iron, zinc or copper supplements

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dysbiosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Oregon State University

    Corvallis, Oregon, 97331, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.